Pascale Witz, GE Healthcare's president and CEO of medical diagnostics, was one of the thousands of life sciences executives at the BIO 2013 International Convention in Chicago this week, and she was in full-scale networking mode.
Venture capitalists have been focusing more on companies that are close to commercialization. But even as the venture capital industry has shifted its priorities to safer bets, VCs like Bob Tepper continue to keep early-stage investment prospects very much in mind.
Cross-town rivals Medtronic and St. Jude Medical are leading the way in getting renal denervation technologies on the U.S. market, and while Medtronic has a definite head start, St. Jude believes it has the know-how to move quickly and capitalize on a market that could be worth close to $3 billion within a decade. Read more >>
Brain-computer interfaces at Brown University have taken another step forward. And the key this time is to go wireless and rechargeable. Brown sees the advance as a next-generation tool to help paralyzed patients move objects with their thoughts, minus being tethered to any connecting wires. Read more >>
February ended with big funding news in the med tech world: HealthCare Royalty Partners' commitment of up to $70 million in debt financing to TearScience, the North Carolina maker of a dry eye treatment device and system. But the type of financing the company secured--royalty funding--is just as noteworthy. Read more >>
Broadly speaking, as far down as the device industry tumbled with the economic crash a few years back, folks are starting to see brief bits of sunshine and are hoping for more.
Just a quick note to tell you that by this time on Monday, we'll be in San Francisco gearing up for some major coverage of JP Morgan 2013.
Welcome back after a nice holiday breather, and Happy New Year to all. While many were on holiday break this last week or so, the device and diagnostics industries were anything but quiet.